FDA pharmacologic class
APOC-III-directed RNA Interaction
2 medicines are in FDA's class of apoc-iii-directed rna interactions: olezarsen (Tryngolza) and plozasiran (Redemplo). 0 of the 2 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are apoc-iii-directed rna interaction?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Olezarsen | Tryngolza | none listed | n/a | No | No current entry | 0 |
| Plozasiran | Redemplo | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)